TREMFYA (guselkumab) Positioned to Become the First and Only IL-23 Inhibitor to Offer Subcutaneous Induction in Ulcerative Colitis as Demonstrated in New Data Through 24 Weeks
May 06, 2025
May 06, 2025
RARITAN, New Jersey, May 6 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:
* * *
TREMFYA (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
TREMFYA subcutaneous induction demonstrates significant rates of clinical remission and endoscopic impr . . .
* * *
TREMFYA (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
TREMFYA subcutaneous induction demonstrates significant rates of clinical remission and endoscopic impr . . .